A systematic review of observational studies found no adverse effects of continued angiotensin‐converting enzyme inhibitor or angiotensin II receptor blocker therapy in patients with COVID‐19,147 and the Taskforce recommended these treatments be maintained. The gene discussed is ACE; the disease is COVID-19.